Skip to main
  1. Stocks
  2. VeraDermics Inc
  3. Forecast
MANE

VeraDermics Inc (MANE) Stock Forecast & Price Target

VeraDermics Inc (MANE) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Veradermics is supported by highly differentiated Phase 3 data for VDPHL01, which in Study 304 met both co-primary endpoints and showed stronger hair-count and patient-reported outcomes than Study 302, with 80% to 85% of patients responding and no cardiac-origin adverse events or treatment-related serious adverse events reported. Across more than 1,000 subjects in two male Phase 3 trials, the drug appears superior to low-dose oral minoxidil and topical Rogaine, while its clean tolerability profile and once-daily or twice-daily dosing could accelerate adoption in a market with high willingness to pay. The investment case is further strengthened by the female opportunity, where a ~30 million diagnosed patient population and promising Phase 2 data de-risk the 1H27 female readout and support peak sales potential in the $2.5 billion to $3 billion range.

Bears say

Veradermics is a clinical-stage biopharmaceutical company whose outlook is weakened by concentration risk, since VDPHL01 is its only value-driving asset and remains in late-stage clinical development with no assurance of success in male and female PHL or FDA approval. Even if approved, the company would enter a highly fragmented U.S. market estimated at $9B where cash-pay dynamics, competing Rx, OTC and procedure options, and the possibility of better efficacy or safety from rivals could pressure pricing and adoption. Its dependence on third-party manufacturing, potential API tariffs, and the need for additional capital as operating expenses rise for trials and commercialization further increase execution and financing risk.

VeraDermics Inc (MANE) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of VeraDermics Inc and is not a guaranteed prediction by Public.com or investment advice.

VeraDermics Inc (MANE) Analyst Forecast & Price Prediction

Get the latest VeraDermics Inc (MANE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in VeraDermics Inc (MANE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About VeraDermics Inc (MANE) Forecast

Analysts have given VeraDermics Inc (MANE) a Strong Buy based on their latest research and market trends.

According to 6 analysts, VeraDermics Inc (MANE) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $169.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $169.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

VeraDermics Inc (MANE)


VeraDermics Inc (MANE) Analyst Forecast & Price Prediction

Get the latest VeraDermics Inc (MANE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in VeraDermics Inc (MANE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MANE stock data and trends